Navigation Links
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Date:11/16/2011

SAN DIEGO, Nov. 15, 2011 /PRNewswire/ -- Ambit Biosciences Inc. today announced the appointment of Michael A. Martino as President, Chief Executive Officer and member of the Board of Directors. Martino brings to Ambit a nearly 30-year track record in leading privately held and publicly traded life sciences companies through late-stage clinical development, fundraising, commercial and business development activities, including new product launches and mergers and acquisitions.  He replaces Alan Lewis, Ph.D., who announced his departure earlier this year and recently left the company after supporting the transition to Martino's appointment.

"We are pleased that Mike, having completed diligence sees what we see: a promising lead drug candidate, quizartinib, with compelling interim data in a high medical need population and valuable earlier-stage assets that together make up an impressive pipeline," said Faheem Hasnain, Ambit's Chairman.  "Mike is joining a talented and committed Ambit team that has successfully moved three drug candidates into the clinic, any one of which could be a lead drug in an earlier stage company, and discovered several promising preclinical compounds. Mike will provide the necessary experience and leadership to drive quizartinib through the approval process and prioritize and focus development of the pipeline."

Martino said, "I am pleased to join Ambit and continue the development of its rich pipeline of early and late-stage programs.  There is tremendous promise in quizartinib where the interim Phase 2 data suggest durable leukemic control in relapsed/refractory acute myeloid leukemia patients with FLT3-ITD mutations who otherwise have very limited treatment options available.  I also look forward to focusing and leading the development of our earlier clinical stage assets, AC430 and AC480, which are targeted at large patient populations with unmet needs."

From 1999 to 2008, Martino served as Presid
'/>"/>

SOURCE Ambit Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ambit Biosciences Announces Transition in Company Leadership
2. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
3. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Neurocrine Biosciences Reports Third Quarter 2011 Results
6. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
7. GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
8. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
9. Amarillo Biosciences Issues Corporate Update
10. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
11. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... The severe flooding that devastated a wide swath of ... the bridges, roads and other infrastructure had been upgraded ... University of Colorado Denver. , "People need to understand ... PhD, associate professor of structural engineering at the CU ... author the study. "There is an assumption that a ...
(Date:10/27/2014)... Kalorama Information says that PCR is demonstrating ... the United States and is the ... said the FDA,s Emergency Use Authorization (EUA) to authorize the ... detection of the Ebola virus was an indication that ... the IVD industry and its biennial survey on diagnostics ...
(Date:10/27/2014)... 2014 Pressure BioSciences, Inc. (OTCQB: PBIO) ... the development and sale of high pressure-based sample ... today announced that Professor Ruedi Aebersold ... reproducible, and robust method to allow – for ... on small needle biopsy samples by mass spectrometry ...
(Date:10/25/2014)... The report “Adipic Acid Market by ... Global Trends & Forecast to 2019” report analyzes ... drivers, opportunities, and trends in different regions. , ... spread through 217 slides and in-depth TOC on ... to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early buyers will ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4
... that going from a positive to a negative is a ... scientists from the National Institute of Standards and Technology (NIST) ... extended the reach of their novel microfluidic system for analyzing ... how the system, meant to analyze real-world, crude mixtures such ...
... help resolve the public debate over America,s future light source ... compact fluorescent lamp. It could be neither. ... new breed of light emitting diode, or LED, that conjures ... an article in the current online issue of the journal ...
... Ariz., Aug. 31, 2011 SynCardia Systems, Inc. ( www.syncardia.com ... today that it has launched company pages on Facebook ... to educate a larger audience about the world,s only FDA, ... have been more than 950 implants of the Total Artificial ...
Cached Biology Technology:Researchers expand capabilities of miniature analyzer for complex samples 2Manufacturing method paves way for commercially viable quantum dot-based LEDs 2Manufacturing method paves way for commercially viable quantum dot-based LEDs 3SynCardia Goes Social on Facebook, Twitter and LinkedIn 2SynCardia Goes Social on Facebook, Twitter and LinkedIn 3SynCardia Goes Social on Facebook, Twitter and LinkedIn 4
(Date:10/28/2014)... of Health (NIH) announced awards to expand the ... National Center for Advancing Translational Sciences (ORDR-NCATS) collaborative ... the network, physician scientists at 22 consortia will ... clinical research and investigate new treatments for patients ... by $29 million in fiscal 2014 funding from ...
(Date:10/27/2014)... researchers have delivered a scientific one-two punch with a ... self-assemble via their sticky ends. , Collagen is the ... bone and the fibrous tissues that support cells and ... better synthetic collagen for tissue engineering and cosmetic and ... has been studying synthetic collagen for a decade, teasing ...
(Date:10/27/2014)... 27, 2014) — Recent breakthroughs may pave the ... infected by parasitic helminths. These flatworms, including tapeworms ... and blood flukes (schistosomes), infect more than 300 ... life years lost due to chronic illness and ... , professor of microbiology, immunology, and tropical medicine, ...
Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3GW researcher adapting breakthrough technologies to combat parasitic worm infections 2
... of the brain are over-stimulated and this leads to ... this process was finally shown last year to be ... stroke. But very few targets for drugs to block ... detailed study, researchers have discovered a previously missing link ...
... an evolutionary geneticist at Fred Hutchinson Cancer Research Center who ... with opposing functions that drives evolutionary change has been ... is among 27 of the nation,s top biomedical scientists to ... more than 1,100 applicants. , "HHMI has a very ...
... Solanaceaea flowering plant family with some species producing foods ... effect against Parkinson,s disease. The study appearing today in ... American Neurological Association and Child Neurology Society, suggests that ... nicotine, such as peppers and tomatoes, may reduce risk ...
Cached Biology News:Researchers discover a missing link in signals contributing to neurodegeneration 2Fred Hutch evolutionary geneticist Harmit Malik selected as an HHMI investigator 2Fred Hutch evolutionary geneticist Harmit Malik selected as an HHMI investigator 3Could eating peppers prevent Parkinson's? 2
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
D4-GDI rabbit polyclonal antibody...
Biology Products: